ADC Therapeutics to Appoint Peter Hug, Ph.D., to Board of Directors
Lausanne, Switzerland, January 3, 2019 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that Peter Hug, Ph.D., will be appointed to its board of directors. Dr. Hug is a 35-year veteran of Roche.
Read full Press Release